Home › Calculator › VERU Dividend Calculator 2026
VERU Dividend DRIP Calculator 2026
75.76% YieldHealthcareVeru Inc. · NASDAQ
Price: $2.64 · Annual div: $2.00/share · Frequency: quarterly · Payout ratio: 50% · Ex-div: TBD
Calculator settings
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When VERU pays your bills
Year your monthly dividend income covers each expense (based on current settings)
Share your VERU snowball 📈
$10,000 in VERU → $66086426561.64M in 10 years · $5,500,112,225,054,615.00/month
About Veru Inc. (VERU) — Dividend Analysis 2026
Veru Inc. operates as a biopharmaceutical firm primarily dedicated to advancing novel therapeutic agents for various types of cancer. Commercially, Veru markets the FC2 internal condom, designed to offer dual protection against both unplanned pregnancies and the transmission of sexually transmitted infections. This product is distributed globally to a diverse clientele, including governmental health departments, UN organizations, non-profit entities, and commercial distributors. Its robust development pipeline features a range of investigational therapies, notably within oncology: Enobosarm, an orally administered selective androgen receptor agonist, is progressing through Phase III clinical trials for treating metastatic breast cancer that is AR+, ER+, and HER2-negative. Sabizabulin is undergoing Phase IIb studies for the same type of metastatic breast cancer. Furthermore, a combination therapy of Enobosarm with abemaciclib is in Phase III for AR+ ER+ HER2- metastatic breast cancer. For metastatic triple-negative breast cancer, Veru is exploring a combination of Sabizabulin (an oral targeted cytoskeleton disruptor) and Enobosarm (a selective androgen receptor agonist) in Phase II trials. The company's portfolio also extends to prostate cancer: Sabizabulin is in Phase II trials for metastatic castration and androgen receptor targeting agent-resistant prostate cancer. VERU-100, a GnRH antagonist peptide delivered via injection, is also in Phase II for advanced hormone-sensitive prostate cancer. Beyond oncology, Veru is investigating other conditions: Zuclomiphene Citrate is in Phase II for managing hot flashes. Sabizabulin has reached Phase III for treating SARS-CoV-2 in high-risk patients susceptible to acute respiratory distress syndrome. Additionally, the firm is developing a novel pharmaceutical formulation aimed at alleviating lower urinary tract symptoms associated with an enlarged prostate in men. Originally established as The Female Health Company in 1971, the corporation adopted the name Veru Inc. in July 2017. Its corporate headquarters are situated in Miami, Florida.
Compare VERU with similar stocks
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full VERU DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open VERU position with:
🌍 VERU Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold VERU.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 75.76% | 72.96% | $7,576 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 64.40% | 61.60% | $6,440 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 60.61% | 57.81% | $6,061 / yr |
| 🇬🇧 UK ISA | 0% | 75.76% | 72.96% | $7,576 / yr |
| 🇬🇧 UK Taxable | 8.75% | 69.13% | 66.33% | $6,913 / yr |
| 🇨🇦 TFSA | 0% | 75.76% | 72.96% | $7,576 / yr |
| 🇨🇦 CA Taxable | 25% | 56.82% | 54.02% | $5,682 / yr |
| 🇦🇺 Super (pension) | 15% | 64.40% | 61.60% | $6,440 / yr |
| 🇦🇺 AU Taxable | 30% | 53.03% | 50.23% | $5,303 / yr |
| 🇩🇪 DE Taxable | 26.375% | 55.78% | 52.98% | $5,578 / yr |
| 🇫🇷 FR Taxable | 30% | 53.03% | 50.23% | $5,303 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 VERU Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
Based on current dividend of $2.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 VERU Dividend Payment Schedule
VERU pays quarterly — 4 times per year. Next ex-div: TBD.
📊 VERU vs Healthcare Benchmarks
How VERU compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for VERU sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ VERU Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| Buy | 2026-08-13 | 1,800 | $2.69 | $4.8K | ||
| A-Award | 2026-05-04 | 604,000 | $2.25 | $1.36M | ||
| A-Award | 2026-05-04 | 164,000 | $2.25 | $369.0K | ||
| A-Award | 2026-05-04 | 102,000 | $2.25 | $229.5K | ||
| A-Award | 2026-05-04 | 97,000 | $2.25 | $218.3K | ||
| A-Award | 2026-05-04 | 100,000 | $2.25 | $225.0K | ||
| A-Award | 2026-05-04 | 104,000 | $2.25 | $234.0K | ||
| A-Award | 2026-05-04 | 160,000 | $2.25 | $360.0K | ||
| A-Award | 2026-05-04 | 160,000 | $2.25 | $360.0K | ||
| A-Award | 2025-12-05 | 27,000 | $2.49 | $67.2K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Geographic Revenue Breakdown
Where VERU earns its moneyRevenue breakdown from latest annual report via FMP. Percentages may not sum to 100% due to rounding.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the VERU dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Veru Inc. (VERU) is currently trading at $2.64, 98% below its 52-week high. The current dividend yield is 75.76% based on an annual payout of $2.00 per share.
VERU (Veru Inc.) — 75.76% Dividend Yield Analysis
Veru Inc. (VERU) is a healthcare stock currently trading at $2.64 with a dividend yield of 75.76%. The company pays an annual dividend of $2.00 per share. The payout ratio of 50% suggests the dividend is well-covered by earnings.
- Above-average yield (75.76%) may signal elevated risk — verify sustainability.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest VERU News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.